Proprietary technology identifies small molecule JAK2 and Pim kinase
SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced data as part of a series of presentations at the 2007 AACR-NCI-EORTC International Conference that describe how its proprietary CLIMB technology was used in lead development and design of small molecule JAK2 and Pim kinase inhibitors (Posters C200 and C208).
Poster C200 (Abstract No. 907)
Effect of small molecule inhibitors of JAK2 kinase on modulating signaling cascades downstream of cytokine receptors
Janus kinases (JAKs) are critical to a number of intracellular signaling pathways. Dysregulation of JAK2 signaling has been implicated in myoproliferative disorders, leukemia, lymphoma and various solid tumors. Utilizing CLIMB, SuperGen's proprietary technology, scientists used a JAK2 crystal structure to build several models that were made into a substrate for screening a large, virtual small molecule library. This process generated a subset of leads that were screened using in silico algorithms to identify "druggable" candidates to pursue.
Poster C208 (Abstract No. 985)
A small molecule inhibitor of Pim-1 kinase with activity in both hematological and solid tumor malignancies
Pim-1 kinase is involved in signaling pathways as a potent inhibitor of programmed cell death (apoptosis). Pim-1 is over expressed in many cancer types, including AML, CML, bladder and oral cancers. Scientists used SuperGen's CLIMB technology to build a model that allowed for the prediction of small molecule inhibitors. Leads were screened to identify those with inhibitory activity with low nanomolar IC50 concentrations. Data support further development of the lead compounds in liquid and solid tumors.
Copies of the poster presentations will be available in the pipeline section of SuperGen's Web site http://www.supergen.com.
"With our CLIMB technology we are able to decrease cycle times while identifying the most druggable candidates," said Dr. James S. Manuso, President and Chief Executive Officer. "This allows us to move at a rapid pace to select candidates that can be advanced into clinical trials."
Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Timothy L. Enns Mary M. Vegh
SuperGen, Inc. SuperGen, Inc.
SVP, Corporate Communications & Manager, Investor Relations
Business Development Tel: (925) 560-2845
Tel: (925) 560-0100 E-mail: firstname.lastname@example.org
|SOURCE SuperGen Inc.|
Copyright©2007 PR Newswire.
All rights reserved